Imaging-Based Liver Transplant Eligibility in Hepatocellular Carcinoma: Analysis of 1,094 Patients Using Liver Imaging Reporting and Data System and Asia-Pacific Guideline-Based Criteria.

IF 10.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Liver Cancer Pub Date : 2026-03-25 DOI:10.1159/000551666
Yeongseok Hwang, Subin Heo, Jihyun An, Seong Kyun Na, Seon-Ok Kim, In-Hye Song, Jean-Charles Nault, Gi-Won Song, Sang Hyun Choi, Ju Hyun Shim
{"title":"Imaging-Based Liver Transplant Eligibility in Hepatocellular Carcinoma: Analysis of 1,094 Patients Using Liver Imaging Reporting and Data System and Asia-Pacific Guideline-Based Criteria.","authors":"Yeongseok Hwang, Subin Heo, Jihyun An, Seong Kyun Na, Seon-Ok Kim, In-Hye Song, Jean-Charles Nault, Gi-Won Song, Sang Hyun Choi, Ju Hyun Shim","doi":"10.1159/000551666","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Accurate imaging diagnosis is essential for evaluating liver transplantation (LT) eligibility in hepatocellular carcinoma (HCC) patients. This study investigated whether pre-transplant imaging assessment using the Liver Imaging Reporting and Data System (LI-RADS) and Asia-Pacific guideline-based criteria could effectively predict long-term prognosis when determining LT eligibility.</p><p><strong>Methods: </strong>From a prospective registry, we analyzed 1,094 patients with a preoperative HCC diagnosis who had dynamic CT available within 1 month before LT. LT eligibility was assessed with Milan criteria (MC) and Up-to-Seven criteria (UTS). Imaging evaluation was performed using the LI-RADS, Asian Pacific Association for the Study of the Liver, Japan Society of Hepatology, and Korean Liver Cancer Association-National Cancer Center guidelines. We compared HCC-related mortality using competing risk analysis, overall survival, and prognostic performance between imaging-based and pathologic assessments.</p><p><strong>Results: </strong>The cohort comprised 158 (14.4%) anti-HCC treatment naïve patients and 936 (85.6%) patients who received anti-HCC treatments in the pre-LT setting. No significant difference in HCC-related mortality was observed between patients meeting imaging-based MC and pathological MC (5-year HCC-related mortality: 8.6-8.7% vs. 6.6%; all <i>p</i> > 0.05). Prognostic performance, assessed by 5-year area under the precision-recall curve and integrated Brier score, showed no significant differences between imaging-based MC and pathological MC groups (all <i>p</i> > 0.05). Similar results were observed for overall survival, UTS-based analyses, and pre-LT treatment subgroup analyses. Concordance between imaging-based MC and pathology-based MC was 84.0-84.4%.</p><p><strong>Conclusion: </strong>Although some discordance between imaging-based and pathology-based LT eligibility criteria was observed, pre-transplant imaging provided prognostic stratification comparable to pathology. Given that comprehensive pathological assessment is unattainable before LT, imaging-based evaluation using both LI-RADS and Asia-Pacific guidelines represents a practical and clinically relevant approach for determining LT eligibility.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":""},"PeriodicalIF":10.5000,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13249434/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551666","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Accurate imaging diagnosis is essential for evaluating liver transplantation (LT) eligibility in hepatocellular carcinoma (HCC) patients. This study investigated whether pre-transplant imaging assessment using the Liver Imaging Reporting and Data System (LI-RADS) and Asia-Pacific guideline-based criteria could effectively predict long-term prognosis when determining LT eligibility.

Methods: From a prospective registry, we analyzed 1,094 patients with a preoperative HCC diagnosis who had dynamic CT available within 1 month before LT. LT eligibility was assessed with Milan criteria (MC) and Up-to-Seven criteria (UTS). Imaging evaluation was performed using the LI-RADS, Asian Pacific Association for the Study of the Liver, Japan Society of Hepatology, and Korean Liver Cancer Association-National Cancer Center guidelines. We compared HCC-related mortality using competing risk analysis, overall survival, and prognostic performance between imaging-based and pathologic assessments.

Results: The cohort comprised 158 (14.4%) anti-HCC treatment naïve patients and 936 (85.6%) patients who received anti-HCC treatments in the pre-LT setting. No significant difference in HCC-related mortality was observed between patients meeting imaging-based MC and pathological MC (5-year HCC-related mortality: 8.6-8.7% vs. 6.6%; all p > 0.05). Prognostic performance, assessed by 5-year area under the precision-recall curve and integrated Brier score, showed no significant differences between imaging-based MC and pathological MC groups (all p > 0.05). Similar results were observed for overall survival, UTS-based analyses, and pre-LT treatment subgroup analyses. Concordance between imaging-based MC and pathology-based MC was 84.0-84.4%.

Conclusion: Although some discordance between imaging-based and pathology-based LT eligibility criteria was observed, pre-transplant imaging provided prognostic stratification comparable to pathology. Given that comprehensive pathological assessment is unattainable before LT, imaging-based evaluation using both LI-RADS and Asia-Pacific guidelines represents a practical and clinically relevant approach for determining LT eligibility.

基于影像学的肝移植在肝细胞癌中的适用性:使用肝影像学报告和数据系统和基于亚太指南标准的1094例患者的分析
准确的影像学诊断对于评估肝细胞癌(HCC)患者的肝移植(LT)资格至关重要。本研究调查了移植前影像学评估使用肝脏影像学报告和数据系统(LI-RADS)和亚太指南为基础的标准是否可以有效地预测长期预后时,确定肝移植资格。方法:从前瞻性注册表中,我们分析了1094例术前HCC诊断的患者,他们在LT前1个月内进行了动态CT检查。LT资格采用米兰标准(MC)和达- 7标准(UTS)进行评估。影像学评估采用LI-RADS、亚太肝脏研究协会、日本肝病学会和韩国肝癌协会-国家癌症中心指南进行。我们使用竞争风险分析、总生存率和基于成像和病理评估的预后表现来比较hcc相关死亡率。结果:该队列包括158例(14.4%)抗hcc治疗naïve患者和936例(85.6%)在肝移植前接受抗hcc治疗的患者。影像MC患者与病理性MC患者的hcc相关死亡率无显著差异(5年hcc相关死亡率:8.6-8.7% vs. 6.6%;均p < 0.05)。通过5年精确召回率曲线下的面积和综合Brier评分评估预后表现,影像学MC组与病理MC组之间无显著差异(均p < 0.05)。在总生存率、基于uts的分析和肝移植前治疗亚组分析中也观察到类似的结果。影像学MC与病理MC的符合率为84.0 ~ 84.4%。结论:尽管观察到基于影像学和基于病理的LT资格标准之间存在一些不一致,但移植前影像学提供了与病理相当的预后分层。鉴于在肝移植前无法进行全面的病理评估,使用LI-RADS和亚太指南进行基于成像的评估是确定肝移植资格的一种实用且临床相关的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Liver Cancer
Liver Cancer Medicine-Oncology
CiteScore
20.80
自引率
7.20%
发文量
53
审稿时长
16 weeks
期刊介绍: Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书